The Lynx Group

Value Propositions

dding trastuzumab to standard cisplatinum/fluoropyrimidine chemotherapy for patients with HER2-positive advanced gastric cancer results in a median survival of 13.8 months, compared with 11.1 months with chemotherapy alone, according to a new study (Lancet. 2010;376 [9742]:687-97. Epub 2010 Aug 19).
Read Article

Washington, DC—Complex partnerships among cancer care stakeholders, including drug manufacturers, are becoming the norm.
Read Article

Chicago, IL—The rising costs of cancer drugs and medical services, along with increased copays and high deductibles for patients, are adding a serious financial hardship to patients diagnosed with cancer, according to Neal J. Meropol, MD, Associate Director, Clinical Programs, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH.
Read Article

Medicare now provides coverage for the only FDA-approved noninvasive stool DNA screening test for colorectal cancer (CRC), after the Centers for Medicare & Medicaid Services (CMS) issued its final National Coverage Determination in October.
Read Article

Page 1 of 11

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: